Noven up on generic fentanyl news

NOVN was up $2.82 (18%) to $18.22 on 2.7 million shares on Monday following the company's announcement post-market last Friday that FDA denied citizen petitions that sought to delay FDA approval of generic fentanyl patches. NOVN, which has an ANDA for its transdermal fentanyl under FDA review to treat chronic pain, said Johnson & Johnson (JNJ) had filed one of the petitions. JNJ markets its Duragesic fentanyl transdermal system. ...